Taiyo Holdings Co., Ltd.
Notice Regarding Differences Between Forecasts and Results for the Second Quarter (Cumulative) of the Fiscal Year Ending March 2027 and Revision of Full-Year Earnings Forecast
Announces differences between cumulative second-quarter results and the second-quarter forecasts for the fiscal year ending March 2027. Revises consolidated full-year earnings forecasts upward — revenue, operating income, ordinary income, and net income attributable to owners of parent — driven by strong performance in the Electronics segment. Medical, Pharmaceuticals, and ICT&S forecasts remain unchanged. Dividend forecast is unchanged.
Key Figures
- Revenue: 152,500 million yen (an increase of 3,400 million yen from the previous forecast of 149,100 million yen)
- Operating Income: 39,600 million yen (an increase of 3,200 million yen from the previous forecast of 36,400 million yen)
- Ordinary Income: 39,700 million yen (an increase of 3,400 million yen from the previous forecast of 36,300 million yen)
- Net Income Attributable to Owners of Parent: 29,600 million yen (an increase of 4,200 million yen from the previous forecast of 25,400 million yen)
- Net Income Per Share: 266.01 yen (revised upward from the previous forecast of 228.26 yen)
AI要約
Key Points of Earnings Revision
Performance in the Electronics segment for the second quarter exceeded expectations due to the yen depreciation and price revisions. Based on the second-quarter results, the full-year forecast has been revised upward: revenue to 152,500 million yen, operating income to 39,600 million yen, ordinary income to 39,700 million yen, and net income attributable to owners of parent to 29,600 million yen. Net income per share has been raised to 266.01 yen. Forecasts for Medical, Pharmaceuticals, and ICT&S remain unchanged.
Segment Impacts and Outlook
By segment, the Electronics business is expected to contribute significantly to revenue, exceeding the previous fiscal results. The full-year dividend forecast remains as announced on April 30, 2026. Taking into account the gain on sale of investment securities recorded as a special gain in the second quarter, the overall earnings forecast has been revised rather than left unchanged. Medical, Pharmaceuticals, and ICT&S retain their current forecasts.
Revenue by Segment
Taiyo Holdings Co., Ltd.
Company overview · Stock price · Financial data · All IR
